Business
ASX hits two-month low as tech rout, vaccine setback fuels 2.5% dive – The Sydney Morning Herald
The ASX 200 plunged to a five-week low on Wednesday after US tech names extended their sell-off and AstraZeneca put its COVID vaccine trial on hold.
Tech stocks were also copping a hiding, mirroring the overnight rout of the NASDAQ to drop 3.2 per cent as a sector. All ASX 200 tech shares were lower, with Afterpay dropping 3.7 per cent to $72.25, Xero losing 2.4 per cent to $93.21, and Wisetech Global 3.5 per cent down at $27.62.
Just 12 of all ASX 200 stocks were ahead, with the heavyweight banks, miners and health firms all down.
CSL fell 2.4 per cent to $281.43 after AstraZeneca has put a hold on the late-stage trial of the highly-anti…
-
Noosa News15 hours agoPill checking to resume in Queensland months after government axed funding
-
Business18 hours agoWhy Austal, Boss Energy, Harvey Norman, and NextDC shares are charging higher today
-
General15 hours agoSocial cohesion fears with weekend rallies set to clash
-
Business19 hours agoASX shares are expensive. Here’s why you should be buying anyway